• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH 11.1% 0.5¢

ALTERITY THERAPEUTICS LIMITED - Corporate Spotlight

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No Corporate Spotlight currently available.

(20min delay)
Last
0.5¢
Change
0.001(11.1%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.4¢ $176.2K 43.05M

Buyers (Bids)

No. Vol. Price($)
5 6530000 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 66172554 56
View Market Depth
Last trade - 15.50pm 19/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 12.5 %)
Open High Low Volume
0.4¢ 0.5¢ 0.4¢ 23124792
Last updated 15.14pm 19/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.